Abstract
A biochip-based method was developed to identify the BCR-ABL mutations that affect the thyrosine kinase domain and determine resistance to targeted therapy with thyrosine kinase inhibitors. The method is based on RT–PCR followed by allele-specific hybridization on a biochip with immobilized oligonucleotide probes. The biochip addresses 11 mutations, which are responsible for up to 85% of imatinib resistance cases. A method to decect the clinically significant mutation T315I was designed on the basis of LNA-clamped PCR and proved highly sensitive, detecting the mutation in clinical samples with a leukemic cell content of 5% or higher. The method was validated using clinical samples from chronic myeloid leukemia (CML) patients with acquired resistance to imatinib. The results of hybridization on biochip were verified by Sanger sequencing.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Volkova M.A. 2001. Klinisheskaya onkogematologiya (Clinical Oncohematology). Moscow: Meditsina.
Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561–566.
Hochhaus A. 2007. Management of Bcr-Abl-positive leukemias with dasatinib. Expert Rev. Anticancer Ther. 7, 1529–1536.
Cortes J., Jabbour E., Kantarjian H., Yin C.C., Shan J., O’ Brien S., Garcia-Manero G., Giles F., Breeden M., Reeves N., Wierda W.G., Jones D. 2007. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 110, 4005–4011.
Kutsev S.I., Vel’ chenko M.V., Mordanov S.V. 2008. Role of BCR-ABL gene mutations in the development of refractivity to imatinib in patients with chronic myeloid leukemia. Klon. Onkogematol. 1, 303–309.
Soverini S., Colarossi S., Gnani A., Rosti G., Castagnetti F., Poerio A., Iacobucci I., Amabile M., Abruzzese E., Orlandi E., Radaelli F., Ciccone F., Tiribelli M., di Lorenzo R., Caracciolo C., et al. 2006. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin. Cancer Res. 12, 7374–7379.
Soverini S., Hochhaus A., Nicolini F.E., Gruber F., Lange T., Saglio G., Pane F., Mü ller M.C., Ernst T., Rosti G., Porkka K., Baccarani M., Cross N.C., Martinelli G. 2011. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European Leukemia Net. Blood. 118, 1208–1215.
Deininger M.W., McGreevey L., Willis S., Bainbridge T.M., Druker B.J., Heinrich M.C. 2004. Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. Leukemia. 18, 864–871.
Baccarani M., Pane F., Saglio G. 2008. Monitoring treatment of chronic myeloid leukemia. Haematologica. 93, 161–169.
Ursan I.D., Jiang R., Pickard E.M., Lee T.A., Ng D., Pickard A.S. 2015. Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: A meta-analysis of clinical trials of tyrosine kinase inhibitors. J. Manag. Care Spec. Pharm. 21, 114–122.
Hanfstein B., Mü ller M.C., Kreil S., Ernst T., Schenk T., Lorentz C., Schwindel U., Leitner A., Hehlmann R., Hochhaus A. 2011. Dynamics of mutant BCR-ABLpositive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica. 96, 60–66.
Emelyanova M.A., Amosenko F.A., Chudinov A.V., Surzhikov S.A., Kazubskaya T.P., Lyubchenko L.N., Nasedkina T.V. 2011. Detection of KRAS mutations in tumor cells using biochips. Mol. Biol. (Moscow). 45 (5), 797–803.
Soverini S., Vitale A., Poerio A., Gnani A., Colarossi S., Iacobucci I., Cimino G., Elia L., Lonetti A., Vignetti M., Paolini S., Meloni G., di Maio V., Papayannidis C., Amabile M., et al. 2011. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCRABL kinase domain mutations at low levels at the time of diagnosis. Haematologica. 96, 552–557.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © A.Yu. Ikonnikova, Yu.E. Yatsenko, O.S. Kremenetskaya, O.V. Vinogradova, D.O. Fesenko, I.S. Abramov, V.A. Ovsepyan, T.V. Nasedkina, 2016, published in Molekulyarnaya Biologiya, 2016, Vol. 50, No. 3, pp. 474–479.
Rights and permissions
About this article
Cite this article
Ikonnikova, A.Y., Yatsenko, Y.E., Kremenetskaya, O.S. et al. Detection of BCR-ABL gene mutations in chronic myeloid leukemia using biochips. Mol Biol 50, 412–416 (2016). https://doi.org/10.1134/S0026893316020084
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S0026893316020084